Movasin, tablets 15 mg 20 pcs

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and antipyretic effects. The mechanism of action is associated with inhibition of prostaglandin synthesis as a result of selective inhibition of enzymatic activity of cyclooxygenase-2 (COX-2), involved in the biosynthesis of prostaglandins in the area of inflammation.

When administered in high doses, prolonged use and individual characteristics of the body, COX-2 selectivity decreases. Suppresses prostaglandin synthesis in the area of inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with relatively selective inhibition of COX-2.

It is less likely to cause gastrointestinal (GI) erosive-ulcerative disease. To a lesser extent, meloxicam acts on cyclooxygenase-1 (COX-1), which is involved in the synthesis of prostaglandins that protect the mucosa of the gastrointestinal tract and are involved in the regulation of blood flow in the kidneys.

Indications

Active ingredient

Composition

1 tablet:

– meloxicam (in terms of 100% substance) 7.5 mg or 15 mg

Supplementary substances:

Povidone-12,600.(polyvinylpyrrolidone low molecular weight medical 12600± 2700),

lactose monohydrate (milk sugar),

Crospovidone (collidon CL, collidon SL-M),

potato starch,

/p>

talc,

magnesium stearate,

microcrystalline cellulose.

How to take, the dosage

The drug Movasin is taken orally with meals in a daily dose of 7.5-15 mg.
Recommended dosing regimen:
– Rheumatoid arthritis: 15 mg Movasin daily. Depending on the therapeutic effect, the dose may be reduced to 7.5 mg per day.
– osteoarthritis: 7.5 mg of Movasin per day. If ineffective, the dose may be increased to 15 mg per day.
– Ankylosing spondylitis: 15 mg of Movasin per day.
Maximum daily dose is 15 mg.

In patients at increased risk of side effects, as well as in patients with severe renal failure who are on hemodialysis, the dose should not exceed 7.5 mg of Movasin per day.

Interaction

Special Instructions

Contraindications

With caution.
Ischemic heart disease (CHD), cerebrovascular disease, compensated heart failure, dyslipidemia/hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, IQ 30-60 ml/min.
Anamnestic data on the development of gastrointestinal ulcers, presence of Helicobacter рylori infection, advanced age, long-term use of NSAIDs, frequent use of alcohol, severe somatic diseases, concomitant therapy with the following drugs:
– anticoagulants (e.g., warfarin);
– antiaggregants (e.g., acetylsalicylic acid, clopidogrel);
– Oral glucocorticosteroids (GCS) (e.g., prednisolone);
– Selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, paroxetine, sertraline).
To decrease the risk of gastrointestinal adverse events, the minimum effective dose should be used for the shortest possible course.

Side effects

Gastrointestinal system: more than 1 % – dyspepsia, including nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1 % – transient increase of “liver” transaminases activity, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, GI bleeding (including hidden gastrointestinal bleeding); less than 0.1less than 0.1 % – gastrointestinal perforation, colitis, hepatitis, gastritis.

Blood organs: over 1% – anemia; 0,1-1% – changes of the blood count, including leukopenia, thrombocytopenia.

Skin: more than 1% – itching, skin rash, 0.1-1% – urticaria, less than 0.1% – photosensitization, bullous rash, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis.

Respiratory system disorders: less than 0.1% – bronchospasm.

Nervous system disorders: more than 1% – dizziness, headache; 0.1-1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.

Cardiovascular system (CVS): more than 1 % – peripheral edema; 0.1-1 % – increase of blood pressure (BP), palpitation, “rushes” of blood to the face.

Urinary system: 0.1-1% – hypercreatininemia and/or increased serum urea; less than 0.1% – acute renal failure; relationship with meloxicam administration is not determined – interstitial nephritis, albuminuria, hematuria.

Sensory organs: less than 0.1% – conjunctivitis, visual impairment, including blurred vision.

Allergic reactions: less than 0.1% – angioedema, anaphylactoid/anaphylactic reactions.

Overdose

Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, GI bleeding, acute renal failure, liver failure, respiratory arrest, asystole.

Treatment: there is no specific antidote; in case of overdose of the drug, gastric lavage, administration of activated charcoal (within the next hour), symptomatic therapy should be carried out. Forced diuresis, urine alkalinization, hemodialysis are ineffective due to high binding of the drug to blood proteins.

Pregnancy use

It is recommended that you consult your doctor before use.

Similarities